Literature DB >> 9314635

Epidemiology, clinical aspects, and biology of IDDM patients under age 40 years. Comparison of data from Antwerp with complete ascertainment with data from Belgium with 40% ascertainment. The Belgian Diabetes Registry.

C L Vandewalle1, M I Coeckelberghs, I H De Leeuw, M V Du Caju, F C Schuit, D G Pipeleers, F K Gorus.   

Abstract

OBJECTIVE: To compare the incidence rate of IDDM in the age-groups 0-14 and 15-39 years in Antwerp, Belgium, and to compare demographic, clinical, and biological data from Antwerp IDDM patients with 92% ascertainment with those from a larger Belgian patient group with 40% ascertainment. RESEARCH DESIGN AND METHODS: Incident cases of IDDM were reported by physicians of the Belgian Diabetes Registry and in Antwerp by several other sources. In Antwerp, completeness of ascertainment was calculated by the capture-recapture method. Demographic and clinical data were collected by questionnaire. Blood was sampled for HLA-DQ genotyping and, in new-inset patients, for autoantibodies.
RESULTS: In Antwerp, the age- and sex-standardized IDDM incidence rates were similar in both age-groups (0-14 years: 11.8/100,000; 15-39 years: 8.9/100,000). The incidence rate decreased in girls above age 15 years (6.9/100,000; P = 0.003) but not in boys (11.0/100,000). Both in Antwerp and Belgium, IDDM was diagnosed more frequently in the 15-39 years age-group (60% of all cases) than under age 15 years, with a lower prevalence of acute symptoms, ketonuria, high-risk HLA-DQ genotype, and autoantibodies against insulin, islet cells, and IA-2, but with a higher prevalence of GAD65 autoantibodies.
CONCLUSIONS: In Antwerp, the incidence rate of IDDM under age 15 years is intermediately high compared with the rates in other European regions. It is similar in the 15-39 years age-group, but with a marked male predominance. Demographic, clinical, and biological data show the same age-dependent heterogeneity as the data collected nationwide, with 40% ascertainment indicating the representativeness of the latter.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9314635     DOI: 10.2337/diacare.20.10.1556

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  24 in total

Review 1.  Epidemiology of type 1 diabetes.

Authors:  David M Maahs; Nancy A West; Jean M Lawrence; Elizabeth J Mayer-Davis
Journal:  Endocrinol Metab Clin North Am       Date:  2010-09       Impact factor: 4.741

2.  Clinical and biological characteristics of diabetic patients under age 40 in Cameroon: relation to autoantibody status and comparison with Belgian patients.

Authors:  Milca Asanghanwa; Frans K Gorus; Ilse Weets; Bart V der Auwera; Folefac Aminkeng; Eric Mbunwe; Patrick Goubert; Katrijn Verhaeghen; Eugene Sobngwi; Janet M Wenzlau; John C Hutton; Daniel G Pipeleers; Bart Keymeulen; Jean-Claude N Mbanya; Chris van Schravendijk
Journal:  Diabetes Res Clin Pract       Date:  2013-11-20       Impact factor: 5.602

Review 3.  Emerging Approaches in Surveillance of Type 1 Diabetes.

Authors:  Sharon Saydah; Giuseppina Imperatore
Journal:  Curr Diab Rep       Date:  2018-07-11       Impact factor: 4.810

Review 4.  The pathogenesis and natural history of type 1 diabetes.

Authors:  Mark A Atkinson
Journal:  Cold Spring Harb Perspect Med       Date:  2012-11-01       Impact factor: 6.915

5.  Proinsulin levels and the proinsulin:c-peptide ratio complement autoantibody measurement for predicting type 1 diabetes.

Authors:  I Truyen; P De Pauw; P N Jørgensen; C Van Schravendijk; O Ubani; K Decochez; E Vandemeulebroucke; I Weets; R Mao; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2005-10-07       Impact factor: 10.122

6.  HLA-DQB1 genotypes, islet antibodies and beta cell function in the classification of recent-onset diabetes among young adults in the nationwide Diabetes Incidence Study in Sweden.

Authors:  E Bakhtadze; H Borg; G Stenström; P Fernlund; H J Arnqvist; A Ekbom-Schnell; J Bolinder; J W Eriksson; S Gudbjörnsdottir; L Nyström; L C Groop; G Sundkvist
Journal:  Diabetologia       Date:  2006-05-31       Impact factor: 10.122

7.  Capture-recapture: a useful methodological tool for counting traffic related injuries?

Authors:  A Morrison; D H Stone
Journal:  Inj Prev       Date:  2000-12       Impact factor: 2.399

8.  Seasonality in clinical onset of type 1 diabetes in belgian patients above the age of 10 is restricted to HLA-DQ2/DQ8-negative males, which explains the male to female excess in incidence.

Authors:  I Weets; L Kaufman; B Van der Auwera; L Crenier; R P A Rooman; C De Block; K Casteels; E Weber; M Coeckelberghs; Z Laron; D G Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2004-04       Impact factor: 10.122

9.  Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2beta) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials.

Authors:  J De Grijse; M Asanghanwa; B Nouthe; N Albrecher; P Goubert; I Vermeulen; S Van Der Meeren; K Decochez; I Weets; B Keymeulen; V Lampasona; J Wenzlau; J C Hutton; D Pipeleers; F K Gorus
Journal:  Diabetologia       Date:  2009-11-29       Impact factor: 10.122

10.  The epidemiology of Type 1 diabetes mellitus is not the same in young adults as in children.

Authors:  K O Kyvik; L Nystrom; F Gorus; M Songini; J Oestman; C Castell; A Green; E Guyrus; C Ionescu-Tirgoviste; P A McKinney; D Michalkova; R Ostrauskas; N T Raymond
Journal:  Diabetologia       Date:  2004-02-05       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.